Business Context and Reporting Period
This Form 8-K Current Report was filed by Neuralstem, Inc. (not Palisade Bio, Inc.) on October 29, 2018, regarding events occurring on October 25, 2018. The filing details the entry into material definitive agreements for a Registered Direct Offering and a concurrent Private Placement of equity securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $2.1 million from the sale of 3,000,000 shares of common stock at $0.70 per share.
- Net Proceeds: Estimated at approximately $1.9 million after deducting placement agent fees and transaction expenses.
- Warrants Issued: 3,000,000 warrants issued to investors (100% of shares sold) with an exercise price of $0.75 and a 5.5-year term.
- Placement Agent Compensation: 7.0% cash fee of gross proceeds plus $60,000 in expenses and 180,000 warrants (6.0% of shares sold) with an exercise price of $0.875.
- Use of Proceeds: Funding for clinical and preclinical programs, working capital, and general corporate purposes.
Material Changes
The filing reports a significant capital raise event rather than a change in operating performance metrics. The company increased its equity capital by issuing new shares and warrants, which will result in dilution to existing shareholders. The filing does not provide comparative financial data (revenue, profit, or cash flow) for the prior period as this is a transaction-specific report.
Outlook, Risks, and Contingencies
Management intends to utilize the net proceeds to advance clinical and preclinical programs. The transaction was subject to customary closing conditions and was anticipated to close on October 29, 2018. The warrants issued to investors are not exercisable for six months following issuance. The filing notes that the warrants and underlying shares were sold without registration under the Securities Act of 1933, relying on exemptions for transactions not involving a public offering and sales to accredited investors.
Investor Verification Checklist
- Verify the exact closing date and final net proceeds received by the company.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Confirm the dilution impact of the 3,000,000 new shares and 3,180,000 total warrants issued.
- Check the company's updated cash position and runway following the receipt of the $1.9 million net proceeds.
- Review the press release (Exhibit 99.1) for any additional strategic context regarding the clinical programs.